Approved treatments for myasthenia gravis

Corticosteroids are powerful anti-inflammatory medications that are widely used in MG and other inflammatory and autoimmune conditions. They prevent the immune system from attacking healthy cells and tissues, helping to minimize inflammatory damage and ease disease symptoms.

Immunosuppressants are a class of medicines that broadly work to suppress or reduce the activity of the immune system. They are widely used in MG and other autoimmune disorders to prevent the immune system from attacking healthy tissues and ease disease symptoms.

Mestinon (pyridostigmine bromide) is an oral acetylcholinesterase inhibitor approved for the treatment of MG. It is available in the form of conventional or extended-release tablets or syrup.

Rystiggo (rozanolixizumab-noli) is an FcRn blocker approved for adults with generalized MG who have antibodies against the acetylcholine receptor or muscle-specific tyrosine kinase. The therapy is given via an under-the-skin (subcutaneous) infusion once weekly in six-week cycles.

Soliris (eculizumab) is a complement inhibitor approved for the treatment of adults with generalized MG who are positive for antibodies against the acetylcholine receptor. It is administered via an into-the-vein (intravenous) infusion, with maintenance doses given every two weeks.

Ultomiris (ravulizumab-cwvz) is a complement inhibitor approved for adults with generalized MG who are positive for antibodies targeting the acetylcholine receptor. It is administered via an into-the-vein (intravenous) infusion, with maintenance doses given every eight weeks.

Vyvgart (efgartigimod alfa-fcab) is an FcRn blocker approved for adults with generalized MG who are positive for antibodies targeting the acetylcholine receptor. The therapy is given via an into-the-vein (intravenous) infusion once weekly in four-week cycles.

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is an FcRn blocker approved for adults with generalized MG who are positive for antibodies targeting the acetylcholine receptor. It is administered via an under-the-skin (subcutaneous) injection once weekly in four-week cycles.

Zilbrysq (zilucoplan) is a complement inhibitor approved for treatment of adults with generalized MG who are positive for antibodies targeting the acetylcholine receptor. It is administered via an under-the-skin (subcutaneous) injection once daily.

Other strategies that can be used to treat myasthenia gravis (MG) patients include intravenous immunoglobulin (IVIG) infusions, plasmapheresis, and thymectomy. These procedures broadly aim to lower the levels of MG-driving autoantibodies in the bloodstream to ease disease symptoms.